Emergent BioSolutions-Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

Emergent Biosolutions (EBS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of$ 0.33. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -133.33%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.12 per share when it actually produced a loss of $1.44, delivering a surprise of -1,100%.Over the last four quarters ...